Impact of chronic oral glucocorticoid treatment on mortality in patients with COVID-19: analysis of a population-based cohort
Objectives While glucocorticoid (GC) treatment initiated for COVID-19 reduces mortality, it is unclear whether GC treatment prior to COVID-19 affects mortality. Long-term GC use raises infection and thromboembolic risks. We investigated if patients with oral GC use prior to COVID-19 had increased mo...
Saved in:
| Main Authors: | Daniel Olsson, Fredrik Nyberg, Huiqi Li, Oskar Ragnarsson, Gudmundur Johannsson, Margret J Einarsdottir, Brian Kibiwott Kirui |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-03-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/3/e080640.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Person-centered support for patients with a pituitary tumor following surgery
by: Sofie Jakobsson, et al.
Published: (2025-01-01) -
Risk of exacerbations, hospitalisation, and mortality in adults with physician-diagnosed chronic obstructive pulmonary disease with normal spirometry and adults with preserved ratio impaired spirometry in Sweden: retrospective analysis of data from a nationwide cohort studyResearch in context
by: Oskar Wallström, et al.
Published: (2025-07-01) -
Aetiology and prognostic risk factors of mortality in patients with pneumonia receiving glucocorticoids alone or glucocorticoids and other immunosuppressants: a retrospective cohort study
by: Chuan Wang, et al.
Published: (2020-10-01) -
Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study.
by: Mar Pujades-Rodriguez, et al.
Published: (2020-12-01) -
Oral pathology induced by excess or deficiency of glucocorticoids in adults
by: Rucsandra Elena Dănciulescu Miulescu, et al.
Published: (2020-10-01)